Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study.

被引：0
|
作者：
Shamash, J.
Jacob, J.
Powles, T.
Agrawal, S.
Mutsvangwa, K.
Saunders, N.
Wilson, P.
Stebbing, J.
机构：
[1] St Bartholomews Hosp, London, England
[2] Univ London Imperial Coll Sci Technol & Med, London, England
[3] St Barthlomews Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2573
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel
    Beardsley, E. K.
    Saad, F.
    Eigl, B.
    Venner, P.
    Hotte, S.
    Winquist, E.
    Ko, Y. J.
    Sridhar, S. S.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] A PHASE II STUDY OF SB939 IN PATIENTS (PTS) WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Eigl, B. J.
    North, S.
    Winquist, E.
    Powers, J.
    Good, J.
    Sharma, M.
    Squire, J.
    Cox, M.
    Eisenhauer, E. A.
    Chi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 304 - 304
  • [43] Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer
    Rushworth, Linda K.
    Loveridge, Carolyn
    Salji, Mark
    MacLeod, Martin
    Mui, Ernest
    Sumpton, David
    Neilson, Matthew
    Hedley, Ann
    Alexander, Laura
    McCartney, Elaine
    Patel, Rachana
    Wallace, Jan
    Delles, Christian
    Jones, Rob
    Leung, Hing Y.
    BJU INTERNATIONAL, 2023, 131 (02) : 236 - 243
  • [44] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
    Mahammedi, H.
    Pouget, M.
    Planchat, E.
    Cure, H.
    Durando, X.
    Van-Praagh, I.
    Savareux, L.
    Abrial, C.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [45] A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
    Laber, Damian A.
    Eatrides, Jennifer
    Jaglal, Michael V.
    Haider, Mintallah
    Visweshwar, Nathan
    Patel, Ankita
    MEDICAL ONCOLOGY, 2020, 37 (10)
  • [46] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [47] Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
    Droz, Jean-Pierre
    Medioni, Jaques
    Chevreau, Christine
    De Mont-Serrat, Helene
    Merger, Michael
    Stopfer, Peter
    Kaiser, Rolf
    Oudard, Stephane
    ANTI-CANCER DRUGS, 2014, 25 (09) : 1081 - 1088
  • [48] Phase I/II study of the androgen receptor antagonist MDV3100 in castration-resistant prostate cancer
    Scher, Howard I.
    Beer, Thomasz
    Higano, Celestia S.
    Danila, Daniel C.
    Shelkey, Julia
    Hirmand, Mohammed
    Hung, David
    Morris, Michael J.
    Larson, Steve M.
    Sawyers, Charles L.
    CANCER RESEARCH, 2008, 68 (09)
  • [49] A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
    Morris, M. J.
    Eisenberger, M. A.
    Pili, R.
    Denmeade, S. R.
    Rathkopf, D.
    Slovin, S. F.
    Farrelly, J.
    Chudow, J. J.
    Vincent, M.
    Scher, H. I.
    Carducci, M. A.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2714 - 2719
  • [50] A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
    Schweizer, Michael T.
    Haugk, Kathleen
    McKiernan, Jozefa S.
    Gulati, Roman
    Cheng, Heather H.
    Maes, Jessica L.
    Dumpit, Ruth F.
    Nelson, Peter S.
    Montgomery, Bruce
    McCune, Jeannine S.
    Plymate, Stephen R.
    Yu, Evan Y.
    PLOS ONE, 2018, 13 (06):
12345